DeepMed Research

GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Lebrikizumab

First Posted Date: 2015-07-01

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 176

Registration Number: NCT02486809

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Atezolizumab
Drug: GDC-0919

First Posted Date: 2015-06-15

Last Posted Date: 2019-10-22

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 158

Registration Number: NCT02471846

Locations: 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 15 locations

A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: GDC-3280

First Posted Date: 2015-06-15

Last Posted Date: 2016-03-17

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 8

Registration Number: NCT02471859

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma

Interventions: Drug: Cobimetinib
Drug: GDC-0994

First Posted Date: 2015-05-29

Last Posted Date: 2018-11-20

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 24

Registration Number: NCT02457793

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 2 locations

A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Crenezumab

First Posted Date: 2015-04-27

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 60

Registration Number: NCT02427243

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
Drug: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody

First Posted Date: 2015-04-07

Last Posted Date: 2022-04-01

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 610

Registration Number: NCT02410512

Locations: 🇫🇷
Gustave Roussy, Villejuif CEDEX, France
🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 24 locations

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

Phase 4

Completed

Conditions: Urticaria

Interventions: Drug: Omalizumab
Drug: Placebo

First Posted Date: 2015-03-19

Last Posted Date: 2018-03-29

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 206

Registration Number: NCT02392624

Locations: 🇺🇸
Florida Ctr-Allergy & Asthma, Miami, Florida, United States
🇺🇸
James Q. Del Rosso, DO, LLC, Las Vegas, Nevada, United States
🇺🇸
Allergy & Asthma Research Center, San Antonio, Texas, United States

and more 37 locations

A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Period 1 treatment
Drug: Period 2 treatment

First Posted Date: 2015-03-17

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 8

Registration Number: NCT02390492

A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Crenezumab dose level 1
Drug: Crenezumb dose level 3
Drug: Placebo
Drug: Crenezumab dose level 2

First Posted Date: 2015-02-03

Last Posted Date: 2019-07-24

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 77

Registration Number: NCT02353598

Locations: 🇺🇸
UCSF - Memory and Aging Center, San Francisco, California, United States
🇺🇸
Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸
Miami Jewish Health Systems, Miami, Florida, United States

and more 10 locations

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Bendamustine
Drug: Obinutuzumab

First Posted Date: 2014-12-19

Last Posted Date: 2020-02-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 102

Registration Number: NCT02320487

Locations: 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸
Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States
🇺🇸
San Juan Oncology Associates, Farmington, New Mexico, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy